Monday, April 18, 2011

Gilead's Truvada fails HIV prevention trial in African women

A study testing Gilead Sciences Inc.’s Truvada as a way to prevent the AIDS virus in African women failed, according to a nonprofit group sponsoring the trial.
The 1,951-woman study, undertaken by FHI and enrolling patients in Kenya, South Africa and Tanzania, was designed to study whether HIV-negative women at a higher risk of being exposed to the virus could safely use a daily dose of Truvada to prevent infection. But half of the 56 new HIV infections occurred in women using Truvada, according to FHI.

No comments:

Post a Comment